MissionIR Articles

FluoroPharma is developing breakthrough molecular imaging agents for use with positron emission tomography (PET) designed to fulfill critical unmet medical needs. These new agents give clinicians crucial tools for the detection and assessment of pathology…

FluoroPharma, a developer of imaging drugs that underpin important diagnostic capabilities of positron emission tomography (PET), targets a fast-growing market. This market is currently over $7 billion in size and is expected to top $15…

FluoroPharma Medical is a New Jersey based developer of advanced imaging pharmaceuticals for use with positron emission tomography (PET). The company provides unique radiopharmaceutical imaging agents, unavailable from other sources, that allow PET technology to…

One of the buzzword terms in modern medicine today is “personalized medicine”. Instead of simply matching a drug or treatment to an over-arching disease based on a one-size-fits-all philosophy, as has been done in the…

FluoroPharma Medical, Inc. is a biopharmaceutical company focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The company…

Earlier this week, LifeTech Capital issued an update on its FluoroPharma Medical coverage. The latest report reiterates the stock as a “Strong Speculative Buy” and sets a $2.50 price target. The entire 23-page report can…

In 1950, the FBI formally announced their Ten Most Wanted list to the world, in an attempt to promote the identification and capture of the most notorious fugitives. If there were a ten most wanted…

For developing businesses, one of the keys to potential growth is to present products that have unique benefits not found elsewhere, providing a decided advantage in the marketplace. In the rapidly expanding field of molecular…

FluoroPharma Medical, developer of breakthrough molecular imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of pathology before clinical manifestation of diseases, announced this morning the release of a company…

FluoroPharma Medical, a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today after the closing bell…

It’s hard to imagine a successful company without a board of directors that is insightful, responsible, and comfortable with any technologies involved in the company’s products or operations. A board is, after all, generally responsible…

FluoroPharma, a developer of advanced tracing chemicals used with positron emission tomography (PET) to help detect heart disease and other problems, recently received a positive report from Life Tech Capital Institutional Research. The points emphasized…

FluoroPharma, a developer of specialized molecular imaging pharmaceuticals used with positron emission tomography (PET) to help detect heart disease and other problems, has stated that it intends to develop its products through the completion of…

FluoroPharma Medical, Massachusetts-based developer of advanced imaging pharmaceuticals for use with positron emission tomography (PET), intends to become the leader in the early detection of coronary artery and alzheimer diseases, two of the most high-profile…

FluoroPharma Medical is a developer of unique, targeted molecular imaging pharmaceuticals used with positron emission tomography (PET). Although the company is focused primarily on the detection of cardiovascular disease (CAD) related processes, the company has…

FluoroPharma Medical intends to lead in the discovery, development, and commercialization of innovative and targeted molecular imaging pharmaceuticals that improve disease detection, management, and overall patient care. The company’s focus has been chemical tracer agents…

In the marketplace, the principal strength of FluoroPharma Medical, developer of tracer agents for use with positron emission tomography (PET), is the uniqueness and effectiveness of their products. Their chemical agents, by highlighting certain biological…

FluoroPharma Medical, a developer of imaging agents for use with positron emission tomography (PET) scanning, helps to make visible subtle biological processes occurring deep within the body. From its founding in 2003, with technology licensed…